Loncastuximab Tesirine provides a CD19-targeting antibody-drug conjugate (ADC) for lymphoma and oncology research. Also known as ADCT-402, it combines a CD19-directed monoclonal antibody with a pyrrolobenzodiazepine (PBD) dimer cytotoxic payload and specifically supports studies of targeted cytotoxicity, B-cell malignancies, DNA damage, and antibody-mediated drug delivery.
Key Features and Benefits
- CD19-Targeting ADC: Combines a CD19-directed monoclonal antibody with a potent PBD dimer payload specifically for targeted lymphoma research.
- PBD Dimer Payload: Contains SG3199, a DNA-crosslinking cytotoxic agent that specifically supports investigation of ADC-mediated cancer cell death.
- CD19 Recognition: Supports investigation of CD19 expression, antibody binding, internalization, and malignant B-cell targeting.
- Cleavable Linker: Uses a protease-cleavable valine-alanine linker specifically designed to facilitate intracellular release of the PBD dimer payload.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of DNA-crosslinking agents to CD19-expressing lymphoma cells.
- DNA Crosslinking Mechanism: The released PBD dimer specifically forms DNA interstrand crosslinks, supporting studies of DNA damage responses and apoptosis.
- Bystander Cytotoxicity: The membrane-permeable payload supports investigation of cytotoxic effects on neighboring tumor cells.
- ADCT-402 Research Platform: Provides a clinically established ADC platform specifically for studying CD19-directed targeting and DNA-crosslinking payload activity.
Applications
- Diffuse Large B-Cell Lymphoma Research: Supports investigation of CD19-targeted ADC mechanisms in diffuse large B-cell lymphoma (DLBCL) models.
- B-Cell Lymphoma Research: Useful for studying targeted cytotoxicity in CD19-expressing B-cell lymphoma models.
- Non-Hodgkin Lymphoma Research: Supports evaluation of CD19-directed ADC strategies in relevant non-Hodgkin lymphoma models.
- CD19-Positive Cancer Research: Useful for investigating antibody targeting and cytotoxic responses in CD19-positive malignant B cells.
- ADC Research: Supports studies of antibody binding, internalization, intracellular processing, and payload release.
- DNA Damage Research: Enables investigation of PBD-mediated DNA interstrand crosslinking and associated cellular responses.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of potent DNA-crosslinking payloads to lymphoma cells.
- Cell-Based Lymphoma Assays: Useful for evaluating CD19-dependent binding, cellular uptake, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of CD19 targeting, DNA crosslinking, and DNA damage-induced cell death.
- Comparative ADC Research: Useful for comparing CD19-targeted ADCs, cleavable linker systems, and DNA-damaging payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and highly potent DNA-crosslinking research materials. Maintain conditions that preserve antibody and conjugate stability.
Loncastuximab Tesirine combines CD19-directed antibody targeting with a potent PBD dimer DNA-crosslinking payload and specifically supports diffuse large B-cell lymphoma, CD19-positive malignancy, ADC, DNA damage, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
